Valuation as at 2026-08-14 · see also the S&P 500 Most Undervalued screen
About Merck & Company, Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Merck & Company, Inc. MRK
Healthcare · Drug Manufacturers - General
Merck & Company, Inc.'s price & financial trends
Each card is labelled with its own reporting period — quarterly where Yahoo provides it for this market, annual otherwise.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per quarter
Free cash flow Per quarter
Dividend per share Per quarter
Value investing scale · Buffett · Dalio · Graham
1 criterion had no data
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 2.5% | 5.1% | 7.6% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 6.58% | 5.58% | 4.58% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.68% + 0.21 × 5.50% = 5.84% · WACC = weighted by 86%/14% capital structure
These numbers come from running Merck & Company, Inc.'s cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or MRK's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with MRK →
More S&P 500 stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the S&P 500 Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Merck & Company, Inc. (MRK) undervalued?
The Base-case DCF estimates intrinsic value at $208.05 vs a price of $135.55 on 2026-08-14 — a +53.5% margin, so the Base case reads undervalued. This is a mechanical output, not advice.